Routes of
administration subcutaneous injection Legal status investigational CAS Number 330988-75-5 | ATC code none Bioavailability N/A ChemSpider none | |
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed. It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.
References
Pegsunercept Wikipedia(Text) CC BY-SA